免疫检查点抑制剂相关心血管不良反应流行病学、发病机制及诊断与治疗进展  

Progress on Epidemiology, Pathogenesis, Diagnosis and Treatment of Immune Checkpoint Inhibitors-Related Cardiovascular Adverse Events

作　　者：于坚 王江涛 刘新亚[2] 史敬 李妍[1,2] 吴莉[1] 张源明[2] YU Jian;WANG Jiangtao;LIU Xinya;SHI Jing;LI Yan;WU Li;ZHANG Yuanming(Department of Cardio-oncology,Tumor Hospital of Xinjiang Medical University,Urumqi 830000,China;Xinjiang Medical University,Urumqi 830000,China;Department of Cardiothoracic Surgery,General Hospital of Xinjiang Military Command,Urumqi 830000,China)

机构地区：[1]新疆医科大学附属肿瘤医院肿瘤心脏病科,新疆维吾尔自治区乌鲁木齐市830000 [2]新疆医科大学,新疆维吾尔自治区乌鲁木齐市830000 [3]新疆军区总医院心胸外科,新疆维吾尔自治区乌鲁木齐市830000

出　　处：《实用心脑肺血管病杂志》2025年第2期130-135,共6页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：新疆维吾尔自治区自然科学基金资助项目(2022D01D76);科技创新领军人才项目(2022TSYCLJ0068)。

摘　　要：免疫检查点抑制剂(ICIs)作为临床治疗肿瘤的一线药物,其治疗过程中会引发一系列免疫相关不良反应(irAEs),涉及多器官、多系统,其中最严重的是ICIs相关心血管不良反应,主要包括心肌炎、心包炎、动脉粥样硬化性心血管疾病、心律失常、血管炎、静脉血栓栓塞等。ICIs相关心血管不良反应发生率虽低,但死亡率较高,已严重影响肿瘤患者的生存质量及远期预后,因此早期识别和及时干预至关重要。本文主要综述了ICIs相关心血管不良反应的流行病学、发病机制、诊断与治疗,以期为临床工作提供参考。Immune checkpoint inhibitors(ICIs),as a first-line drug for clinical treatment of tumors,can cause a series of immune-related adverse events(irAEs)during the treatment,involving multiple organs and systems.The most serious of them are ICIs-related cardiovascular adverse events,including myocarditis,pericarditis,atherosclerotic cardiovascular disease,arrhythmia,vasculitis,and venous thromboembolism.Although the incidence of ICIs-related cardiovascular adverse events is low,the mortality rate is high,which has seriously affected the quality of life and long-term prognosis of cancer patients.Therefore,early identification and timely intervention are very important.This article mainly reviews the epidemiology,pathogenesis,diagnosis and treatment of ICIs-related cardiovascular adverse events,in order to provide reference for clinical work.

关 键 词：抗肿瘤药 免疫 免疫检查点抑制剂 心血管不良反应 综述 

分 类 号：R979.1[医药卫生—药品]